- Home
- MTEX vs EVAX Comparison
MTEX vs EVAX Comparison
Compare MTEX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- EVAX
- Stock Information
- Founded
- MTEX 1993
- EVAX 2008
- Country
- MTEX United States
- EVAX Denmark
- Employees
- MTEX N/A
- EVAX N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTEX Health Care
- EVAX Health Care
- Exchange
- MTEX Nasdaq
- EVAX Nasdaq
- Market Cap
- MTEX 14.2M
- EVAX 14.3M
- IPO Year
- MTEX 1999
- EVAX 2021
- Fundamental
- Price
- MTEX $7.99
- EVAX $1.68
- Analyst Decision
- MTEX
- EVAX Strong Buy
- Analyst Count
- MTEX 0
- EVAX 2
- Target Price
- MTEX N/A
- EVAX $11.00
- AVG Volume (30 Days)
- MTEX 2.2K
- EVAX 27.9K
- Earning Date
- MTEX 11-12-2024
- EVAX 10-31-2024
- Dividend Yield
- MTEX N/A
- EVAX N/A
- EPS Growth
- MTEX N/A
- EVAX N/A
- EPS
- MTEX N/A
- EVAX N/A
- Revenue
- MTEX $121,552,000.00
- EVAX $3,295,000.00
- Revenue This Year
- MTEX N/A
- EVAX $4,845.21
- Revenue Next Year
- MTEX N/A
- EVAX $30.30
- P/E Ratio
- MTEX N/A
- EVAX N/A
- Revenue Growth
- MTEX N/A
- EVAX N/A
- 52 Week Low
- MTEX $6.75
- EVAX $1.59
- 52 Week High
- MTEX $10.51
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- MTEX 52.49
- EVAX 20.75
- Support Level
- MTEX $7.50
- EVAX $1.59
- Resistance Level
- MTEX $8.52
- EVAX $2.63
- Average True Range (ATR)
- MTEX 0.30
- EVAX 0.23
- MACD
- MTEX -0.04
- EVAX -0.09
- Stochastic Oscillator
- MTEX 57.78
- EVAX 5.96
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.